Protein microarrays for personalized medicine

Clinical Chemistry

Volumn 56, Issue 3, 2010, Pages 376-387

  Yu, Xiaobo ^a   Schneiderhan Marra, Nicole ^a   Joos, Thomas O ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CD40 ANTIGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; FAS LIGAND; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 12P40; INTERLEUKIN 18; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MYOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANTES; SCATTER FACTOR; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN D BINDING PROTEIN; VITRONECTIN;

ASPIRATION BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMICAL PARAMETERS; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DNA MICROARRAY; ENTERITIS; GENE EXPRESSION; GENETIC ANALYSIS; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOASSAY; IN VITRO STUDY; MOLECULAR MECHANICS; NONHUMAN; OROPHARYNX CARCINOMA; OVARY CANCER; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; RNA ANALYSIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SYSTEMS BIOLOGY; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDITY;

BIOLOGICAL MARKERS; DIAGNOSIS; HUMANS; INDIVIDUALIZED MEDICINE; PROTEIN ARRAY ANALYSIS;

EID: 77649194471     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.137158     Document Type: Review

References (72)

1. Personalized Medicine Coalition. http://www. personalizedmedicinecoalition.org/ (Accessed January 2010).
2. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of geneexpression patterns. Nature 2008;452:564 -70.
3. Wong SH. Pharmacogenomics and personalized medicine. In: Dasgupta A, ed. Handbook of drug monitoring methods: therapeutics and drugs of abuse. New York: Humana Press; 2007. p 211-23.
4. Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008;54:1770 -9.
5. Joos T, Kroeger P. New frontiers in microarray technology development. Curr Opin Biotechnol 2008;19:1-3.
6. Pollard HB, Srivastava M, Eidelman O, Jozwik C, Rothwell S, Mueller GP, et al. Protein microarray platforms for clinical proteomics. Proteomics Clin Appl 2007:934 -52.
7. Ramachandran N, Srivastava S, LaBaer J. Applications of protein microarrays for biomarker discovery. Proteomics Clin Appl 2008;2:1444 -59.
8. Yu X, Xu D, Cheng Q. Label-free detection methods for protein microarrays. Proteomics 2006;6: 5493-503.
9. Hartmann M, Roeraade J, Stoll D, Templin MF, Joos TO. Protein microarrays for diagnostic assays. Anal Bioanal Chem 2009;393:1407-16.
10. Yu X, Schneiderhan-Marra N, Hsu HY, Bachmann J, Joos TO. Protein microarrays: effective tools for the study of inflammatory diseases. Methods Mol Biol 2009;577:199 -214.
11. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol 2006;208:595- 606.
12. Kingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006;5: 310 -20.
13. Pawlak M, Schick E, Bopp MA, Schneider MJ, Oroszlan P, Ehrat M. Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics 2002;2:383-93.
14. VanMeter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008;7: 1902-24.
15. Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF 3rd. Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. Adv Exp Med Biol 2008;610:177- 86.
16. Espina V, Wulfkuhle J, Calvert VS, Liotta LA, Petricoin EF 3rd. Reverse phase protein microar-rays for theranostics and patient-tailored therapy. Methods Mol Biol 2008;441:113-28.
17. Liotta LA, Petricoin EF. Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem 2008;54:3-5.
18. Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008;54:e1-10.
19. Mathivanan S, Ahmed M, Ahn NG, Alexandre H, Amanchy R, Andrews PC, et al. Human Proteinpedia enables sharing of human protein data. Nat Biotechnol 2008;26:164 -7.
20. Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008;7: 1508-17.
21. Joos TO, Berger H. The long and difficult road to the diagnostic market: protein microarrays. Drug Discov Today 2006;11:959-61.
22. Zangar RC, Daly DS, White AM. ELISA microarray technology as a high-throughput system for cancer biomarker validation. Expert Rev Proteomics 2006;3:37- 44.
23. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72.
24. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2872- 81.
25. Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS ONE 2009;4: e4599.
26. LaBaer J. So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res 2005;4:1053-9.
27. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113:273- 8.
28. Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Baldertorp B, Ferno M, et al. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 2008; 44:472- 80.
29. Pearlberg J, Degot S, Endege W, Park J, Davies J, Gelfand E, et al. Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells. Cold Spring Harb Symp Quant Biol 2005;70:449 -59.
30. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of differentially expressed proteins in ovarian cancer using highdensity protein microarrays. Proc Natl Acad Sci U S A 2007;104:17494 -9.
31. Ramachandran N, Raphael JV, Hainsworth E, Demirkan G, Fuentes MG, Rolfs A, et al. Nextgeneration high-density self-assembling functional protein arrays. Nat Methods 2008;5: 535-8.
32. Hall DA, Ptacek J, Snyder M. Protein microarray technology. Mech Ageing Dev 2007;128:161-7.
33. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007;6:1115-22.
34. Zhu H, Hu S, Jona G, Zhu X, Kreiswirth N, Willey BM, et al. Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray. Proc Natl Acad Sci U S A 2006;103:4011- 6.
35. Schmid KE, Keasey SL, Pittman P. Analysis of the human immune response to vaccinia by use of a novel protein microarray suggests that antibodies recognize less than 10% of the total viral proteome. Proteomics Clin Appl 2008;2:1528 -38.
36. Ingvarsson J, Wingren C, Carlsson A, Ellmark P, Wahren B, Engstrom G, et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008;8: 2211-9.
37. Song XC, Fu G, Yang X, Jiang Z, Wang Y, Zhou GW. Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining. Mol Cell Proteomics 2008;7:163-9.
38. Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 2008;7:1490 -9.
39. Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther 2008;8:1495-505.
40. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008;28: 477-87.
41. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115:1750 -5, 1755.e1.
42. Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, et al. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 2008;68: 872- 82.
43. Huang RP. An array of possibilities in cancer research using cytokine antibody arrays. Expert Rev Proteomics 2007;4:299 -308.
44. Linkov F, Ferris RL, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Gooding W, et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl 2008;2:1575- 85.
45. Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, et al. Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res 2008;14:3345-53.
46. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 2009;11:R22.
47. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007;11:R49.
48. Torrence AE, Brabb T, Viney JL, Bielefeldt-Ohmann H, Treuting P, Seamons A, et al. Serum biomarkers in a mouse model of bacterialinduced inflammatory bowel disease. Inflamm Bowel Dis 2008;14:480 -90.
49. Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008;153:188 -95.
50. Fabre S, Guisset C, Tatem L, Dossat N, Dupuy AM, Cohen JD, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009;155:395- 402.
51. Allen C, Duffy S, Teknos T, Islam M, Chen Z, Albert PS, et al. Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007;13:3182-90.
52. Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007;46:166 -72.
53. Petricoin EF 3rd, Espina V, Araujo RP, Midura B, Yeung C, Wan X, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007; 67:3431- 40.
54. Sheehan KM, Gulmann C, Eichler GS, Weinstein JN, Barrett HL, Kay EW, et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 2008;27:323-31.
55. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004;3:179 -96.
56. Albeck JG, MacBeath G, White FM, Sorger PK, Lauffenburger DA, Gaudet S. Collecting and organizing systematic sets of protein data. Nat Rev Mol Cell Biol 2006;7:803-12.
57. Knickerbocker T, Chen JR, Thadhani R, MacBeath G. An integrated approach to prognosis using protein microarrays and nonparametric methods. Mol Syst Biol 2007;3:123.
58. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007;1:1- 48.
59. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005;4:1123-33.
60. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24: 971-83.
61. Zhang X. Biomarker validation: movement towards personalized medicine. Expert Rev Mol Diagn 2007;7:469 -71.
62. NMI Technologietransfer GmbH. BioChipNet. http://www.biochipnet.de (Accessed February 2010).
63. Servoss SL, Gonzalez R, Varnum S, Zangar RC. High-throughput analysis of serum antigens using sandwich ELISAs on microarrays. Methods Mol Biol 2009;520:143-50.
64. Hornauer H, Klause U, Müller H-J, Vieth F, Risse B. IMPACT - eine Protein Array Technologie für diediagnostischeAnwendungderZukunft. BIOspektrum 2004:564 -5.
65. Xu D, Xu D, Yu X, Liu Z, He W, Ma Z. Label-free electrochemical detection for aptamer-based array electrodes. Anal Chem 2005;77:5107-13.
66. Taussig MJ, Stoevesandt O, Borrebaeck CA, Bradbury AR, Cahill D, Cambillau C, et al. ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods 2007;4:13-7.
67. Kricka LJ, Master SR, Joos TO, Fortina P. Current perspectives in protein array technology. Ann Clin Biochem 2006;43:457- 67.
68. Randox Laboratories Ltd. http://www.randox.com/ (Accessed February 2010).
69. Kricka LJ, Master SR. Validation and quality control of protein microarray-based analytical methods. Mol Biotechnol 2008;38:19 -31.
70. Master SR, Bierl C, Kricka LJ. Diagnostic challenges for multiplexed protein microarrays. Drug Discov Today 2006;11:1007-11.
71. Woodcock J, Woosley R. The FDA Critical Path Initiative and its influence on new drug development. Annu Rev Med 2008;59:1-12.
72. Bril A, Canet E. [The Innovative Medicine Initiative (IMI)]. Med Sci (Paris) 2008;24:885-90. [French]